iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC

- Adenosine portfolio clinical data readouts anticipated in second half of 2024, including inupadenant’s Phase 2 A2A-005 and EOS-984’s Phase 1 trial

- EOS-984 preclinical data demonstrating novel mechanism of action in the adenosine pathway anticipated in second quarter of 2024

- Cash balance and investment balance of $644.9 million as of September 30, 2023 expected to provide runway through 2026

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.

“Over the past twelve months, the TIGIT competitive landscape has substantially evolved, further positioning iTeos and GSK as a potential leader with our high-quality TIGIT:PD-1 doublet, belrestotug + dostarlimab. We remain very encouraged by our progress ahead of a defining year for the company where we anticipate multiple data readouts across our IO portfolio throughout 2024, including three Phase 2 trials, one Phase 1 trial, and the unveiling of preclinical data and the novel mechanism of action for EOS-984,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos. “We believe 2024 will be an exciting year where we anticipate furthering our ambition to bring best- and first-in-class science to patients and validate our vision of building a pipeline of highly differentiated IO therapies.”

Program Highlights

Belrestotug (EOS-448/GSK4428859A): IgG1 anti-TIGIT monoclonal antibody targeting first-line non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) in collaboration with GSK

• Preparation underway for Phase 3 registrational studies that will evaluate the belrestotug + dostarlimab doublet
  
• GALAXIES Lung-201: topline data from Phase 2 platform trial assessing belrestotug + dostarlimab doublet in first-line advanced/metastatic non-small cell lung cancer anticipated in 2024
  
• GALAXIES H&N-202: enrollment ongoing in Phase 2 platform study assessing belrestotug + dostarlimab doublet and a triplet with GSK’s investigational anti-CD96 antibody (GSK’608) in first-line patients with PD-L1 positive recurrent / metastatic HNSCC